Nikhil Lalwani is President and Chief Executive Officer of ANI Pharmaceuticals Inc (ANIP). The company reported total compensation of $10,278,620 for fiscal year 2025.
| Salary | $837,409 |
|---|---|
| Bonus | $0 |
| Stock awards | $7,848,711 |
| Option awards | $0 |
| Non-equity incentive plan | $1,572,500 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $20,000 |
| Total | $10,278,620 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure ANI Pharmaceuticals Inc filed April 9, 2026, accession 0001023024-26-000039.
| Peer-group chief executive median | $8,309,350 |
|---|---|
| Difference from that median | $1,969,270 |
| Percentile within the disclosed peer group | 80th |
| Peers with a disclosed figure | 5 |
Medians and percentiles are computed across the peer group ANI Pharmaceuticals Inc discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Nikhil Lalwani this page | President and Chief Executive Officer | $10,278,620 |
| Christopher Mutz | Senior Vice President, Head of Rare Disease | $3,396,694 |
| Stephen Carey | Senior Vice President, Finance and Chief Financial Officer | $3,251,862 |
| Meredith Cook | Senior Vice President, General Counsel and Corporate Secretary | $2,318,421 |
| Ori Gutwerg | Senior Vice President, Generics | $2,309,559 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full ANI Pharmaceuticals Inc compensation brief.
Nikhil Lalwani's compensation sits inside ANI Pharmaceuticals Inc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.